Valeant Offers to Buy Botox Maker Allergan With Pershing Support

Valeant Pharmaceuticals International Inc. (VRX) offered to buy Allergan Inc. for about $152.89 a share in a cash-and-stock deal that will give the Canadian company the Botox wrinkle treatment.

Allergan investors would receive $48.30 in cash and 0.83 percent of a Valeant share in the deal, Valeant said in a statement today. Pershing Square Management LP, Allergan’s largest shareholder with 9.7 percent of shares outstanding, supports the purchase, Valeant said. The per-share value of the offer is based on yesterday’s closing price.

To contact the editor responsible for this story: Bruce Rule at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.